Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Return on Capital Employed of 58.11% for Q1 2026, down 267.0% year-over-year from 34.8% in Q1 2025, and down 2.76% quarter-over-quarter from 56.55% in Q4 2025.
Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Return on Capital Employed for 11 consecutive years, with 58.11% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 267.0% year-over-year to 58.11%; the TTM figure through Mar 2026 stood at 58.11% (down 267.0% YoY), while the FY2025 annual figure was 48.32%, down 125.0% from the prior year.
- Return on Capital Employed declined to 58.11% in Q1 2026 per NTLA's latest filing, from 56.55% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.19% in Q1 2023 and bottomed at 60.45% in Q2 2025.
- Historically, Return on Capital Employed has averaged 46.25% across 5 years, with a median of 44.54% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 1898 bps — and 2023, when it soared 359 bps.
- Intellia Therapeutics' Return on Capital Employed stood at 38.97% in 2022, then retreated by 14 bps to 44.54% in 2023, then retreated by 12 bps to 49.87% in 2024, then dropped by 13 bps to 56.55% in 2025, then retreated by 3 bps to 58.11% in 2026.
- Business Quant data shows NTLA's Return on Capital Employed at 58.11% in Q1 2026, 56.55% in Q4 2025, and 58.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -58.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.12% |
| Mar 31, 2026 | -58.11% |
| Dec 31, 2025 | -56.55% |
| Sep 30, 2025 | -58.50% |
| Jun 30, 2025 | -60.45% |
| Mar 31, 2025 | -55.44% |
| Dec 31, 2024 | -49.87% |
| Sep 30, 2024 | -49.94% |
| Jun 30, 2024 | -46.77% |
| Mar 31, 2024 | -43.75% |
| Dec 31, 2023 | -44.54% |
| Sep 30, 2023 | -40.75% |
| Jun 30, 2023 | -36.19% |
| Mar 31, 2023 | -31.19% |
| Dec 31, 2022 | -38.97% |
| Sep 30, 2022 | -44.34% |
| Jun 30, 2022 | -38.24% |
| Mar 31, 2022 | -32.58% |
| Dec 31, 2021 | -22.53% |
| Sep 30, 2021 | -25.37% |